181 related articles for article (PubMed ID: 12039935)
1. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.
Crul M; de Klerk GJ; Swart M; van't Veer LJ; de Jong D; Boerrigter L; Palmer PA; Bol CJ; Tan H; de Gast GC; Beijnen JH; Schellens JH
J Clin Oncol; 2002 Jun; 20(11):2726-35. PubMed ID: 12039935
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.
Zujewski J; Horak ID; Bol CJ; Woestenborghs R; Bowden C; End DW; Piotrovsky VK; Chiao J; Belly RT; Todd A; Kopp WC; Kohler DR; Chow C; Noone M; Hakim FT; Larkin G; Gress RE; Nussenblatt RB; Kremer AB; Cowan KH
J Clin Oncol; 2000 Feb; 18(4):927-41. PubMed ID: 10673536
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors.
Punt CJ; van Maanen L; Bol CJ; Seifert WF; Wagener DJ
Anticancer Drugs; 2001 Mar; 12(3):193-7. PubMed ID: 11290865
[TBL] [Abstract][Full Text] [Related]
4. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.
Adjei AA; Croghan GA; Erlichman C; Marks RS; Reid JM; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Bruzek LM; Atherton P; Thibault A; Palmer PA; Kaufmann SH
Clin Cancer Res; 2003 Jul; 9(7):2520-6. PubMed ID: 12855626
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.
Kurzrock R; Albitar M; Cortes JE; Estey EH; Faderl SH; Garcia-Manero G; Thomas DA; Giles FJ; Ryback ME; Thibault A; De Porre P; Kantarjian HM
J Clin Oncol; 2004 Apr; 22(7):1287-92. PubMed ID: 15051776
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors.
Eskens FA; Awada A; Cutler DL; de Jonge MJ; Luyten GP; Faber MN; Statkevich P; Sparreboom A; Verweij J; Hanauske AR; Piccart M;
J Clin Oncol; 2001 Feb; 19(4):1167-75. PubMed ID: 11181683
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.
Cohen SJ; Gallo J; Lewis NL; Alpaugh RK; Gentner L; Rogatko A; Yeslow G; Schol J; Verhaeghe T; Zannikos P; Palmer PA; Weiner LM; Meropol NJ
Cancer Chemother Pharmacol; 2004 Jun; 53(6):513-8. PubMed ID: 14760509
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.
Cortes J; Albitar M; Thomas D; Giles F; Kurzrock R; Thibault A; Rackoff W; Koller C; O'Brien S; Garcia-Manero G; Talpaz M; Kantarjian H
Blood; 2003 Mar; 101(5):1692-7. PubMed ID: 12411300
[TBL] [Abstract][Full Text] [Related]
9. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
Karp JE; Lancet JE; Kaufmann SH; End DW; Wright JJ; Bol K; Horak I; Tidwell ML; Liesveld J; Kottke TJ; Ange D; Buddharaju L; Gojo I; Highsmith WE; Belly RT; Hohl RJ; Rybak ME; Thibault A; Rosenblatt J
Blood; 2001 Jun; 97(11):3361-9. PubMed ID: 11369625
[TBL] [Abstract][Full Text] [Related]
10. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
Caponigro F
Anticancer Drugs; 2002 Sep; 13(8):891-7. PubMed ID: 12394276
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer.
Adjei AA; Mauer A; Bruzek L; Marks RS; Hillman S; Geyer S; Hanson LJ; Wright JJ; Erlichman C; Kaufmann SH; Vokes EE
J Clin Oncol; 2003 May; 21(9):1760-6. PubMed ID: 12721252
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors.
Castaneda C; Meadows KL; Truax R; Morse MA; Kaufmann SH; Petros WP; Zhu Y; Statkevich P; Cutler DL; Hurwitz HI
Cancer Chemother Pharmacol; 2011 Feb; 67(2):455-63. PubMed ID: 20972873
[TBL] [Abstract][Full Text] [Related]
13. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer.
Rao S; Cunningham D; de Gramont A; Scheithauer W; Smakal M; Humblet Y; Kourteva G; Iveson T; Andre T; Dostalova J; Illes A; Belly R; Perez-Ruixo JJ; Park YC; Palmer PA
J Clin Oncol; 2004 Oct; 22(19):3950-7. PubMed ID: 15459217
[TBL] [Abstract][Full Text] [Related]
14. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.
Kurzrock R; Kantarjian HM; Cortes JE; Singhania N; Thomas DA; Wilson EF; Wright JJ; Freireich EJ; Talpaz M; Sebti SM
Blood; 2003 Dec; 102(13):4527-34. PubMed ID: 12947010
[TBL] [Abstract][Full Text] [Related]
15. Farnesyl transferase inhibitors in the treatment of breast cancer.
Kelland LR
Expert Opin Investig Drugs; 2003 Mar; 12(3):413-21. PubMed ID: 12605564
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.
Johnston SR; Hickish T; Ellis P; Houston S; Kelland L; Dowsett M; Salter J; Michiels B; Perez-Ruixo JJ; Palmer P; Howes A
J Clin Oncol; 2003 Jul; 21(13):2492-9. PubMed ID: 12829668
[TBL] [Abstract][Full Text] [Related]
17. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies.
Karp JE
Semin Hematol; 2001 Jul; 38(3 Suppl 7):16-23. PubMed ID: 11523024
[TBL] [Abstract][Full Text] [Related]
18. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.
Kelland LR; Smith V; Valenti M; Patterson L; Clarke PA; Detre S; End D; Howes AJ; Dowsett M; Workman P; Johnston SR
Clin Cancer Res; 2001 Nov; 7(11):3544-50. PubMed ID: 11705875
[TBL] [Abstract][Full Text] [Related]
19. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
Cohen SJ; Ho L; Ranganathan S; Abbruzzese JL; Alpaugh RK; Beard M; Lewis NL; McLaughlin S; Rogatko A; Perez-Ruixo JJ; Thistle AM; Verhaeghe T; Wang H; Weiner LM; Wright JJ; Hudes GR; Meropol NJ
J Clin Oncol; 2003 Apr; 21(7):1301-6. PubMed ID: 12663718
[TBL] [Abstract][Full Text] [Related]
20. Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial.
Lara PN; Law LY; Wright JJ; Frankel P; Twardowski P; Lenz HJ; Lau DH; Kawaguchi T; Gumerlock PH; Doroshow JH; Gandara DR
Anticancer Drugs; 2005 Mar; 16(3):317-21. PubMed ID: 15711184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
